Brian Rini, MD, Oncology, Nashville, TN

BrianIRiniMDFASCO

Oncology Nashville, TN

Genitourinary Oncology, Hematologic Oncology

Brian Rini, MD, FASCO Professor of Medicine Chief of Clinical Trials Vanderbilt-Ingram Cancer Center

Dr. Rini is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rini's full profile

Already have an account?

Education & Training

  • University of Chicago
    University of ChicagoFELLOWSHIP
  • University of Chicago
    University of ChicagoRESIDENCY
  • The Ohio State University College of Medicine
    The Ohio State University College of MedicineMEDICAL_SCHOOL
  • The University of Notre DameOTHER_TRAINING

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 2020 - 2020
  • TN State Medical License
    TN State Medical License 2019 - 2021
  • OH State Medical License
    OH State Medical License 2005 - 2020
  • CA State Medical License
    CA State Medical License 2001 - Present
  • IL State Medical License
    IL State Medical License 1995 - 2002
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • Professional Excellence 2011
  • Outstanding Mentor ASCO/AACR Workshop on Methods, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Targeted therapy for patients with renal-cell carcinoma.  
    Rini BI, Lancet Oncol. 2011 Nov;12(12):1085-7. Epub 2011 Oct 17. PMID: 22015058
  • Commentary on "the impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor target...  
    Choueiri, T.K., Xie, W., Kollmannsberger, C., North, S., Knox, J.J., Lampard, J.G., McDermott, D.F., Rini, B.I., Heng, D.Y., Kidney Cancer Center, Dana Farber Cancer I..., J. Urol 2011; 185:60-6
  • Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.  
    Garcia JA, Mekhail T, Elson P, Triozzi P, Nemec C, Dreicer R, Bukowski RM, Rini BI, BJU Int. 2010 PMID: 20840548
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma.
    Rini BI, Halabi S, Rosenberg JE, Genitourinary Cancer Symposium, abstract 350
  • Metastatic renal cell carcinoma (mRCC) with sarcomatoid component treated with VEGF-targeted therapy.
    Bukowski RM, Garcia JA, Rini BI, Genitourinary Cancer Symposium, abstract 348
  • A prospective trial of Sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab.
    Rini BI, Hutson TE, Elson P, Garcia JA, Genitourinary Cancers Symposium, abstract 346
  • Join now to see all

Lectures

  • Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediat... 
    2019 ASCO Annual Meeting - 6/1/2019
  • A Phase III Trial of Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Metastatic Renal Cell Carcinoma. 
    Genitourinary Cancer Symposium, Oral Presentation
  • Join now to see all

Other

  • Kidney cancer: Does hypothyroidism predict clinical outcome? 
    Rini B, Nat Rev Urol. 2011 Jan;8(1):10-1. PMID: 21116300
  • Editorial comment. 
    Rini BI, Shah SN, Urology. 2010 May;75(5):1114-5
  • Editorial Comment. 
    Campbell SC, Rini BI, J Urol. 182(6):2599-600
  • Join now to see all

Press Mentions

  • ESMO Virtual Congress 2020: Comparison of Long-Term Survival and Cost-Effectiveness of First-Line Treatment Options in Advanced Renal Cell Carcinoma with Intermediate or Poor Prognostic Risk
    ESMO Virtual Congress 2020: Comparison of Long-Term Survival and Cost-Effectiveness of First-Line Treatment Options in Advanced Renal Cell Carcinoma with Intermediate or Poor Prognostic RiskSeptember 21, 2020
  • A COVID-19-Cancer Interplay
    A COVID-19-Cancer InterplayOctober 07, 2020
  • Brian Rini, MD, on Salvage Ipilimumab and Nivolumab in RCC
    Brian Rini, MD, on Salvage Ipilimumab and Nivolumab in RCCSeptember 02, 2020
  • Join now to see all

Grant Support

  • Therapeutic Modulation Of Cox-2-Induced Immunosuppression In Metastatic RCCNational Cancer Institute2007–2008

Professional Memberships